Lite Strategy, Inc.

As reported on the call, MEI had $100.7 million in cash, cash equivalents and short-term investments and no outstanding debt as of June 30, 2023. Management said this cash is sufficient to fund operations for at least the next 12 months and through clinical data readouts from the ongoing and planned voruciclib and ME-344 Phase 1/1b programs. The company did not provide quarterly revenue, EPS, or gross margin figures on the call; instead, management said the recognized revenue is entirely KKC-driven collaboration revenue and is not anticipated to continue going forward. On costs, Jay File said fiscal 2023 R&D was about $52.5 million, with about $26 million specifically related to zandelisib, and that R&D should fall significantly as COASTAL and TIDAL wind down. Forward milestones: voruciclib data are expected in early calendar 2024, and ME-344 data are expected in the first half of 2024.

David Urso framed the quarter as a transition to a standalone strategy after terminating the Infinity merger agreement, saying MEI is committed to its two clinical-stage programs. His tone was constructive and optimistic, emphasizing that voruciclib and ME-344 each have novel mechanisms, clear biologic hypotheses, and meaningful market opportunities in combination with current standards of care. He repeatedly tied the company’s near-term value story to upcoming data readouts rather than to commercial execution.

Jay File kept his remarks brief and focused on liquidity and runway. He said MEI ended June 30, 2023 with $100.7 million in cash, cash equivalents and short-term investments, with no debt, and that this should fund operations for at least 12 months and through the planned clinical readouts. In response to questions, he also noted that fiscal 2023 R&D was about $52.5 million, with about $26 million tied to zandelisib, and that those expenses should continue to roll off as the related trials wind down.

Analysts focused first on runway and whether management’s ‘at least 12 months’ cash guidance was conservative; Urso said it was appropriate for the current Phase 1 plans and that further development beyond that is data-driven. Another question asked whether top-line revenue would continue; management said the revenue being recognized is collaboration revenue from KKC and is not expected to continue. On voruciclib, management said the upcoming readout should include safety, PK, biomarker data such as MCL-1 and MYC, and possibly a recommended Phase 2 dose. Analysts also pressed on ME-344’s 20% four-month PFS threshold and how it compares with historical data; management said the threshold was a floor agreed with investigators, based on regorafenib-era benchmarks, and that the readout’s meaning will depend heavily on the patients enrolled.